A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
Charles S. Fuchs(University of Southern California), Keith Stuart(Brigham and Women's Hospital), Michele Vincitore(Dana-Farber Cancer Institute), Robert J. Mayer(Applied Natural Sciences), David P. Ryan(East Carolina University), Jeffrey W. Clark(Massachusetts General Hospital), Craig C. Earle(Canadian Partnership Against Cancer), M. Kulke(Harvard University), Haesook Kim(Dana-Farber Cancer Institute)
Cited by 95
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k